Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Truffle Capital, founded in 2001, is a Paris-based venture capital firm managing approximately €500 million in assets. The firm has backed 79 companies, achieving multiple IPOs on Euronext. Key founders include Patrick Kron and Philippe Pouletty.
Truffle Capital invests between €2 million and €15 million in Series A, B, and C rounds, primarily targeting biotech, fintech, digital health, and medtech sectors. They emphasize European companies with global potential and typically prefer startups with recurring revenues of at least €5 million.
Notable portfolio companies include Carmat (artificial heart), Vexim (acquired for spinal surgery), AB Science (oncology), and Pixium Vision (bionic vision). Truffle Capital has achieved 46 exits, including 15 IPOs on Euronext.
Submit your pitch through their form at this link.
As of October 1, 2025, Truffle Capital has made 5 investments in the last 12 months, continuing its active engagement in the biotech and fintech sectors.
Truffle Capital focuses on disruptive innovations in life sciences and fintech, investing primarily in European companies with strong growth potential.
Yes, Truffle Capital typically acts as a lead investor, providing significant capital to support portfolio companies.
The firm invests between €2 million and €15 million in each round, depending on the stage and potential of the startup.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.